[go: up one dir, main page]

AR035586A1 - Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn - Google Patents

Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn

Info

Publication number
AR035586A1
AR035586A1 ARP010104453A ARP010104453A AR035586A1 AR 035586 A1 AR035586 A1 AR 035586A1 AR P010104453 A ARP010104453 A AR P010104453A AR P010104453 A ARP010104453 A AR P010104453A AR 035586 A1 AR035586 A1 AR 035586A1
Authority
AR
Argentina
Prior art keywords
quinolin
imidazo
manufacture
derivative
vaccine
Prior art date
Application number
ARP010104453A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9899764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR035586(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR035586A1 publication Critical patent/AR035586A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una composición de vacuna, caracterizada porque comprende (i) un componente adyuvante que comprende un derivado de 1H-imidazo[4,5-c]quinolin-4-amina y (ii) un componente inmunogénico que comprende una secuencia nucleotídica que codifica para un péptido o proteína antigénica asociada con un estado de enfermedad. Reivindicación 18: El uso de un derivado de 1H-imidazo[4,5-c]quinolin-4-amina en la fabricación de un medicamento para aumentar las respuestas inmunes iniciadas por un péptido antigénico, dicho péptido es expresado como resultado de la administración a un mamífero, de una secuencia nucleotídica que codifica para dicho péptido.
ARP010104453A 2000-09-20 2001-09-20 Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn AR035586A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0023008.6A GB0023008D0 (en) 2000-09-20 2000-09-20 Improvements in vaccination

Publications (1)

Publication Number Publication Date
AR035586A1 true AR035586A1 (es) 2004-06-16

Family

ID=9899764

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104453A AR035586A1 (es) 2000-09-20 2001-09-20 Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn

Country Status (24)

Country Link
US (3) US20040076633A1 (es)
EP (1) EP1318835B1 (es)
JP (1) JP2004509150A (es)
KR (1) KR100876263B1 (es)
CN (1) CN1197620C (es)
AR (1) AR035586A1 (es)
AT (1) ATE401097T1 (es)
AU (2) AU2001287908B2 (es)
BR (1) BR0113982A (es)
CA (1) CA2422863A1 (es)
CZ (1) CZ2003792A3 (es)
DE (1) DE60134866D1 (es)
ES (1) ES2309086T3 (es)
GB (1) GB0023008D0 (es)
HU (1) HUP0301180A3 (es)
IL (1) IL154947A0 (es)
MX (1) MXPA03002453A (es)
MY (1) MY138978A (es)
NO (1) NO20031274L (es)
NZ (1) NZ524792A (es)
PL (1) PL360895A1 (es)
TW (1) TWI287453B (es)
WO (1) WO2002024225A1 (es)
ZA (1) ZA200302231B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
PT1733735T (pt) 1998-05-22 2017-06-16 Ottawa Hospital Res Inst Métodos e produtos para induzir imunidade mucosal
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US20060088542A1 (en) * 2002-03-19 2006-04-27 Powdermed Limited Imidazoquinoline adjuvants for vaccines
AU2003216852B2 (en) * 2002-03-19 2008-09-11 Glaxo Group Limited Imidazoquinolineamines as adjuvants in HIV DNA vaccination
GB0206461D0 (en) * 2002-03-19 2002-05-01 Glaxo Group Ltd Improvements in vaccination
CA2495570C (en) * 2002-08-15 2012-12-04 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
EP1590348A1 (en) 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US8673932B2 (en) * 2003-08-12 2014-03-18 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
JP2007504145A (ja) * 2003-08-25 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 免疫刺激性の組み合わせおよび治療
EP1658035A4 (en) * 2003-08-25 2007-08-22 3M Innovative Properties Co ADMINISTRATION OF MODIFIERS OF IMMUNE RESPONSE
JP5128815B2 (ja) 2003-08-27 2013-01-23 スリーエム イノベイティブ プロパティズ カンパニー アリールオキシ置換およびアリールアルキレンオキシ置換イミダゾキノリン
WO2005023190A2 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
ES2544477T3 (es) 2003-10-03 2015-08-31 3M Innovative Properties Company Imidazoquinolinas sustituidas con alcoxi
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CN1906193A (zh) 2003-11-14 2007-01-31 3M创新有限公司 肟取代的咪唑环化合物
EP1682544A4 (en) * 2003-11-14 2009-05-06 3M Innovative Properties Co HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS
MXPA06005910A (es) 2003-11-25 2006-08-23 3M Innovative Properties Co Sistemas de anillo imidazo sustituido y metodos.
EP1701955A1 (en) * 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
JP2007517044A (ja) * 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
CA2559863A1 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) * 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7915281B2 (en) * 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US20070259881A1 (en) * 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006009826A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006026760A2 (en) * 2004-09-02 2006-03-09 3M Innovative Properties Company 1-amino imidazo-containing compounds and methods
US20070243215A1 (en) * 2004-10-08 2007-10-18 Miller Richard L Adjuvant for Dna Vaccines
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
US8461174B2 (en) * 2004-12-30 2013-06-11 3M Innovative Properties Company Treatment for cutaneous metastases
ES2392647T3 (es) * 2004-12-30 2012-12-12 3M Innovative Properties Company Compuestos tetracíclicos quirales que inducen la biosíntesis de interferón
EP1831221B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Substituted chiral fused 1,2 imidazo 4,5-c ring compounds
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
AU2006232377A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
JP2008538550A (ja) 2005-04-01 2008-10-30 コーリー ファーマシューティカル グループ，インコーポレイテッド ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての１−置換ピラゾロ（３，４−ｃ）環状化合物
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
CN101300254A (zh) * 2005-09-09 2008-11-05 科利制药集团公司 N－{2－[4－氨基－2－(乙氧基甲基)－1H－咪唑并[4,5－c]喹啉－1－基]－1,1－二甲基乙基}甲磺酰胺的酰胺和氨基甲酸酯衍生物和方法
CA2628131C (en) 2005-11-04 2012-03-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
US8088788B2 (en) 2006-03-15 2012-01-03 3M Innovative Properties Company Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods
WO2007106854A2 (en) * 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2007121491A1 (en) * 2006-04-25 2007-11-01 Intercell Ag Hcv vaccinations
US20090060928A1 (en) * 2006-05-26 2009-03-05 Jean-Claude Bystryn Topical Toll Like Receptor Ligands as Vaccine Adjuvants
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California purine analogs
US20100129403A1 (en) * 2006-06-20 2010-05-27 Transgene S.A. Recombinant viral vaccine
CA2655933C (en) 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
WO2008008432A2 (en) * 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
CN100450484C (zh) * 2006-10-11 2009-01-14 北京科信必成医药科技发展有限公司 一种咪喹莫特混悬溶液及其凝胶剂
PL2510946T3 (pl) 2007-02-07 2015-12-31 Univ California Koniugaty syntetycznych agonistów tlr i ich zastosowania
WO2008100598A2 (en) * 2007-02-15 2008-08-21 Mannkind Corporation A method for enhancing t cell response
US8709445B2 (en) 2007-07-31 2014-04-29 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Vaccination with killed but metabolically active (KBMA) protozoans with toll-like receptor agonists
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
WO2011068226A1 (ja) * 2009-12-03 2011-06-09 株式会社アウレオ マクロファージ貪食能活性化組成物および／またはマクロファージにおけるサイトカイン産生促進組成物
CN101850117B (zh) * 2010-06-03 2012-05-30 国家兽用生物制品工程技术研究中心 一种复方免疫佐剂及疫苗
MX359517B (es) 2010-08-17 2018-10-01 3M Innovative Properties Company Star Composiciones, formulaciones y metodos de compuestos lipidicos modificadores de respuestas inmunitaria.
MX352373B (es) 2011-03-31 2017-11-22 Adc Therapeutics Sa Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno.
EP2717919B1 (en) 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
WO2012167081A1 (en) 2011-06-03 2012-12-06 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
IN2014CN04690A (es) 2012-01-09 2015-09-18 Alethia Biotherapeutics Inc
GB201310578D0 (en) 2013-06-13 2013-07-31 Univ Nottingham Trent Electroactive actuators
WO2015023649A2 (en) 2013-08-12 2015-02-19 3M Innovative Properties Company Peptides for enhancing transdermal delivery
CA3001249C (en) 2015-10-12 2023-10-17 Reflow Medical, Inc. Stents having protruding drug-delivery features and associated systems and methods
WO2017184735A1 (en) * 2016-04-19 2017-10-26 Ifm Therapeutics, Inc Nlrp3 modulators
US10556903B2 (en) 2016-04-19 2020-02-11 Innate Tumor Immunity, Inc. NLRP3 modulators
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
WO2018217897A1 (en) * 2017-05-23 2018-11-29 David Weiner Compositions and method for inducing an immune response
SG11202002174SA (en) 2017-09-13 2020-04-29 Sanofi Pasteur Human cytomegalovirus immunogenic composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5958895A (en) * 1996-10-23 1999-09-28 American Home Products Corporation DNA vaccines for herpes simplex virus
GB9818627D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination

Also Published As

Publication number Publication date
HK1057700A1 (en) 2004-04-16
AU2001287908B2 (en) 2005-06-30
CN1197620C (zh) 2005-04-20
IL154947A0 (en) 2003-10-31
JP2004509150A (ja) 2004-03-25
NZ524792A (en) 2004-09-24
DE60134866D1 (de) 2008-08-28
CZ2003792A3 (cs) 2004-12-15
AU8790801A (en) 2002-04-02
NO20031274L (no) 2003-05-19
KR20040023566A (ko) 2004-03-18
CA2422863A1 (en) 2002-03-28
US20070248614A1 (en) 2007-10-25
EP1318835B1 (en) 2008-07-16
CN1473051A (zh) 2004-02-04
ZA200302231B (en) 2004-05-05
ES2309086T3 (es) 2008-12-16
BR0113982A (pt) 2003-08-19
PL360895A1 (en) 2004-09-20
TWI287453B (en) 2007-10-01
MY138978A (en) 2009-08-28
HUP0301180A3 (en) 2005-11-28
US20110002953A1 (en) 2011-01-06
WO2002024225A1 (en) 2002-03-28
US20040076633A1 (en) 2004-04-22
HUP0301180A2 (hu) 2004-03-01
MXPA03002453A (es) 2003-06-19
EP1318835A1 (en) 2003-06-18
ATE401097T1 (de) 2008-08-15
KR100876263B1 (ko) 2008-12-26
NO20031274D0 (no) 2003-03-19
GB0023008D0 (en) 2000-11-01

Similar Documents

Publication Publication Date Title
AR035586A1 (es) Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn
Tagliabue et al. Vaccine adjuvants: the dream becomes real
ES2257068T3 (es) Mezclas de adyuvantes de cpg y saponinas y metodos de empleo de las mismas.
NO20015073D0 (no) Vaksiner
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
NO20010922L (no) Fremgangsmåte for DNA vaksinering
BRPI0414381A (pt) composição de adjuvante, composição ou composições imunogênica(s), composição de vacina, processo para a fabricação de uma composição imunogênica, composição ou composições farmacêutica(s), kit, métodos para tratar um paciente que sofre de, ou que é suscetìvel a, um tumor, para incrementar uma resposta imune de um mamìfero a um antìgeno e para suscitar uma resposta imune em m mamìfero contra um estado de doença, usos de uma imidazoquinolina ou derivado da mesma e gm-csf e dos componentes
ES2185762T3 (es) Vacunas contra la peste.
EA200601761A1 (ru) Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
ES2121820T3 (es) Vacuna de conjugados de polisacaridos de neumococos.
ES2352780B2 (es) Lipopolisacárido de ochrobactrum intermedium contra la sepsis.
Beignon et al. Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG‐containing oligodeoxynucleotide and effective priming of influenza virus‐specific CD4+ T cells
JP2005526085A5 (es)
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
CA2466937C (fr) Antigene mycobacterien recombinant de type hemagglutinine de liaison a l'heparine methylee, procedes de preparation et compositions immunogenes comprenant un tel antigene
DE60136928D1 (de) Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme
Qin et al. CpG ODN enhances immunization effects of hepatitis B vaccine in aged mice
Habibi et al. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model
Farnós et al. The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice
AR053661A1 (es) Peptido para entregar vacunas via mucosas
CN115996751A (zh) 与离子液体佐剂有关的方法和组合物
Ekström et al. Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions
EP2501396B1 (en) Low antigen-dose immunization for maximizing t-helper cell 1 (th1) immunity against disease
BR0208980A (pt) Vacinas incluindo ifn do tipo i como um adjuvante e processos relacionados a esses
Yasuda et al. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies

Legal Events

Date Code Title Description
FB Suspension of granting procedure